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ABSTRACT
OBJECTIVE: The objective of this systematic review is to determine whether or not “Are
inverse agonists of the Histamine H3 receptor effective in reducing excessive daytime sleepiness
(EDS) in individuals with sleep disorders?”
DESIGN: Review of two randomized controlled trials and one cross-sequential pilot study. All
studies were primary sources, published in the English language and from 2008-2017.
DATA SOURCES: A single-blind, placebo controlled, cross-sequential study comparing an H3
inverse agonist to placebo in narcoleptics. Two randomized, double-blind, placebo controlled
studies; one in narcoleptic patients and one in obstructive sleep apnea (OSA) patients. All studies
found using PubMed and Cochrane databases.
OUTCOMES MEASURED: All three trials assessed the efficacy of using an H3 inverse agonist
to reduce EDS symptoms in patients with either narcolepsy or obstructive sleep apnea. EDS
severity was assessed using the Epworth Sleepiness Scale (ESS), an eight question selfadministered questionnaire that assess an individual’s likelihood of falling asleep in normal
everyday settings. Scores range 0-24, with a higher score correlating with more severe EDS.
RESULTS: The pilot study done by Lin J-S et al. showed a significant reduction in ESS score of
4.86 (p =0.0006). The RCT done by Dauvilliers (2013) concluded with a significant ESS score
reduction of -3.0 (p= 0.024) when compared to placebo. The final study involving OSA patients
done by Herring et al. showed a larger reduction in ESS scores when treated with an H3 inverse
agonist compared to treatment with a placebo. These results were not proven to be statistically
significant.
CONCLUSIONS: These results suggest that H3 inverse agonists are effective at reducing EDS
symptoms in patients with sleep disorders. All three studies provided evidence of reduced ESS
scores, indicating a perceived improvement in EDS symptoms with the use of an H3 inverse
agonist. Two of the three studies provided statistically significant reductions ESS scores when
compared to placebo.
KEY WORDS: Narcolepsy, Sleep Apnea, Excessive Daytime Sleepiness (EDS)

1

Peters | H3 Receptor Inverse Agonist & EDS |

Introduction
“I’m always tired” is one of the few complaints physicians and physician assistants dread
to hear. Fatigue and excessive tiredness is a sensitive but also nonspecific indicator for many
underlying conditions in a variety of medical settings. Determining the cause of a patient’s
fatigue can be a long and frustrating process for both the doctor and the patient. However, what
is even more frustrating is knowing the source of the fatigue but not being able to adequately
treat the patient. Unfortunately, this is the discouraging truth for many patients with sleep
disorders who suffer from excessive daytime sleepiness (EDS).
EDS is a universal symptom of almost all sleep disorders. It is defined as the inability to
maintain wakefulness and alertness during the major waking episodes of the day, with sleep
occurring unintentionally or at inappropriate times almost daily for at least three months. 1 EDS
affects nearly 20% of the US population,2 however it’s true prevalence is difficult to estimate due
to the subjective nature of the symptoms and inconsistencies in terminology (ie – fatigue,
drowsiness, sluggishness). EDS can lead to cognitive impairment, immune suppression, and
decreased quality of life. If not properly managed, EDS can lead to unnecessary health care costs
and motor vehicle accidents. Narcolepsy and Obstructive Sleep Apnea (OSA) are two sleep
disorders commonly recognized for severe EDS.
Narcolepsy is a sleep disorder that effects 1 out of every 2,000 Americans.3 It is well
known for its unique “sleep attacks” in which individuals suddenly fall into a deep sleep at a
moment’s notice. The etiology of narcolepsy is still not fully understood, but it is thought to be
caused by a deficiency in hypocretin, a brain chemical that regulates sleep. It’s most debilitating
symptom is EDS, which occurs in 100% of individuals with the disorder.4 Treatment involves
the use of drugs to try to regulate the sleep-wake cycle. Modafinil is the current gold standard in
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treating the symptoms of EDS in narcoleptic patients.4 Additional CNS stimulants, such as
methylphenidate and amphetamines, may also be used when modafinil is insufficient. Prior to
modafinil, sodium oxybate was considered the first line treatment, and is still frequently used
today.
It is estimated that 22 million Americans suffer from obstructive sleep apnea.3 EDS is
present in 70% of patients with OSA and is the most common daytime symptom.5 The defining
pathological event of OSA is the closure of the upper airway during sleep, resulting in apneic
events, or pauses in breathing.6 The closure of the airway is thought to occur due to the failure of
the genioglossus and other upper airway dilator muscles. Failure of these muscles can be a result
of several factors including obesity, neck circumference >17 inches, and tonsillar hypertrophy. 6
Apneic events are relieved by sudden brain activation and arousal. The cyclic nature of these
apneic events and brain activation leads to fragmented sleep and poor sleep quality. Continuous
positive airway pressure (CPAP) is considered the gold standard of treatment for OSA. With
optimal adherence, CPAP improves sleep quality. However, one study showed that even with
optimal adherence, 22% of patients reported residual symptoms of EDS.7 This, in combination
with already low adherence rates, EDS continues to be a major problem in this population.
The prevalence of sleep disorders comes with a high cost. In the US, it is estimated to be
between $50 and $100 billion dollars. Patients with narcolepsy are often on full disability and
annual medical costs are often twice as much as matched controls.8 In the workplace, sleepiness
results in the loss of $54 million/year due to reduced productivity9 and individuals with EDS are
three times more likely to be involved in a workplace accident.10 Another study estimated that
810,000 automobile accidents resulting in 1400 fatalities are attributable to OSA in a single
year.11 By treating the same OSA patients with CPAP at 70% adherence, it was estimated that it
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would prevent 500,000 collisions.11 However, this means that even with treatment with the
current gold standard, there would still be 310,000 collisions with 400 fatalities at the cost of
$4.8 billion. It is clear that an adjunctive treatment to EDS is needed.
It has been well speculated that histamine plays a role in sleep and arousal ever since the
sedating properties of antihistamines were first observed in the 1940’s.12 However, it hasn’t been
until recently that we have begun to fully understand the complexity of the histaminergic system.
In 1983, histamine H3 receptors were discovered to provide negative feedback on the synthesis
of histamine. While activation of H1 and H2 receptors via histamine excite and arouse various
neurons, H3 receptor activation actually has the opposite effect. When histamine binds to an H3
receptor it triggers a negative feedback to restrict further histamine synthesis and release. An
inverse agonist of this receptor would block the effects of the H3 receptor and exert the opposite
effect by suppressing spontaneous receptor signaling.13 In other words, it would promote the
release of more histamine and arousal. The discovery if this new H3 receptor has become a
potential target for the pharmaceutical treatment of EDS.
Objective:
The objective of this systematic review is to determine whether or not inverse agonists of
the Histamine H3 receptor are effective in reducing excessive daytime sleepiness (EDS) in
individuals with sleep disorders.
Methods:
A detailed search of the PubMed database was completed between November 2016 and
January 2017 using the keywords “narcolepsy”, “EDS”, and “sleep apnea”. Cochrane Systematic
Reviews was also searched to rule out any previous systematic reviews or meta-analysis on the
topic. Articles were selected based on publication date, relevance to practice and importance to
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patient-oriented outcomes (POEMs). Inclusion criteria included placebo-controlled trials
comparing the efficacy of a H3 inverse agonist to that of a placebo. Two studies also compared
the efficacy of modafinil compared to H3 inverse agonists and placebo. All studies included
participants over the age of 18 with a clinically diagnosed sleep disorder published in an English
peer reviewed journal after 2006. All participants reported having an ESS score of at least 10 or
above prior to the start of the respected studies. Two double-blinded RCT’s comparing the
pharmacological effects of a H3 inverse agonist were included in this review; one was a
crossover design and the other was a parallel design. Due to the sparsity of published
interventions involving H3 inverse agonists, a single-blind pilot study was also included in this
review.
Study
Lin J-S
(2008)

Table 1: Demographics & Characteristics of included studies
Type
# Pts Age
Inclusion Criteria:
Exclusion Criteria:
(yrs)
Cross
22
28-54 Diagnosis of narcolepsy ESS Score < 10
Sequenti
al
Study
Single
blind

Dauvill
iers
(2013)

RCT
Double
blind/
parallel
group
design

W/
D
1

via the International
Classifications of Sleep
Disorders

14 ♂
8♀
95
51 ♂
44
♀

Age > 18 yo
Must be diagnosed with
narcolepsy and
confirmed via
polysomnogram.
Self – reported EDS for
more than 3 months.
A ESS Score > 14

1 week of daily:
40 mg capsule of tiprolisant
(a histamine H3 inverse
agonist)
vs.
Visually matched placebo

Presence of severe EDS
for 3 months or greater

21-52

Interventions:

Women of child bearing
age not on a birth
control method
Use of any
investigational drug
within 30 days of
screening
Any disorder that could
be the main cause of
EDS.
Hx of substance abuse
Cardiovascular, renal,
hepatic disorders, or
psychiatric disorder.

16

8 weeks of treatment.
Pitolisant (Histamine H3
inverse agonist)
vs.
Visually matched placebo
vs.
Modafinil
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(2013)

RCT

125

Double
blind/
crossove
r design

18-64

100
♂
25
♀

>18 yo
Diagnosed OSA and
managed with cont.
positive airway pressure
therapy
Use of compliant CPAP
treatment for > 2months
ESS >10
Clinical global
impressions-severity
scale rating >4

History of sleep
disorders other than
OSA.
Medical conditions other
than OSA that would
explain EDS.
6 MWT sessions
performed at the end of
placebo screening; pt’s
excluded if they stayed
awake throughout the
30-min test for more
than 2 of the 6 sessions.

22

5

2 weeks each of daily:
Modafinil (200mg),
Visually matched placebo,
and
MK-0249 (5, 8, 10, or
12mg)
One week washout between
intervention periods.

Outcomes Measured:
Reduction in EDS was measured in all three studies by using the Epworth Sleepiness
Scale (ESS). The ESS is a self-administered questionnaire that assesses the likelihood of falling
asleep in a variety of everyday situations. Respondents rate, on a 4-point scale (0-3), their
probability of dozing off while engaged in eight different activities. The total ESS score is the
sum of all 8 items, and can range from 0-24. The higher the score, the higher the person’s sleep
propensity in daily settings, or their ‘daytime sleepiness’. The ESS questionnaire only takes 2-3
minutes to complete, and is the most widely used clinical instrument for evaluating sleepiness.14
Results:
The two RCTs, and one pilot study included in this review compared the efficacy of H3
receptor inverse agonists in reducing excessive daytime sleepiness when compared to placebo in
individuals diagnosed with narcolepsy or obstructive sleep apnea.
The single-blind pilot trial by Lin J-S et al.15 was one of the first studies that looked at the
effects of a H3 inverse agonist in humans. The study consisted of 22 patients with diagnosed
narcolepsy. All participants were recruited from the sleep medicine practices of 4 participating
centers. All stimulant medications were stopped 3 days before the study. Participants consumed a
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capsule daily containing a placebo for 1 week, followed by 1 week of daily consumption of 40
mg of tiprolisant, an H3 inverse agonist. The study concluded with 21 participants. One
participant failed to complete the study after experiencing adverse effects from the
discontinuation of her previous medications prior to the study. The principal end-point of the
study was changes in ESS scores at the end of each week. Each patient acted as his/her control.
All analyses were performed on the intention-to-treat population (n=22). The mean ESS score
after 1 week of placebo and 1 week of tiprolisant were 16.66 (± 4.86) and 11.81 (± 6.11)
respectively (Table 2).
The t-tests, which compared the variables measured during the tiprolisant period versus
placebo period, were performed only when both values were available (n=21). Significant
differences in ESS were seen with Tiprolisant when compared to baseline and placebo.
Specifically, the ESS score under tiprolisant treatment showed a 4.86 ± 5.12 point reduction
when compared to placebo, and a 5.86 ± 5.51 reduction when compared to baseline (Table 3).
Table 2: Mean ESS Score (± SD)
Mean ESS Score (± SD)
Baseline
17.55 (± 3.89)
After Placebo period

16.66 (± 4.86)

After Tiprolisant period

11.81 (± 6.11)

Table 3: Treatment Effect (Point Reduction [95% CI]; p-value)
Tiprolisant vs placebo
Tiprolisant vs Baseline
4.86 (2.22 to 7.56)
5.86 (3.42 to 8.34)
p= 0.0006
p < 0.0001
11 patients experienced 23 adverse events during tiprolisant treatment as compared to 7
patients experiencing 13 adverse events during placebo treatment. Among the 22 patients the
most significant adverse events during the tiprolisant period were headache (n=5), nausea (n=4),
insomnia (n=2), malaise (n=2), and sweating (n=2). The majority of the adverse events (95%)
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occurred during the first 3 days of treatment. None of these adverse events led to treatment
cessation and 21/22 fully complied with the prescribed treatments.
The conclusion of the pilot study led to a much larger study 5 years later. This doubleblind RCT by Dauvillers et al. 16 involved 94 narcoleptic patients from 32 centers in five
European countries. Eligible participants were at least 18 years old with self-reported EDS for
more than 3 months. Participants were randomly assigned to a treatment group, in which they
received either a placebo, Modafinil or Pitolisant, an H3 receptor inverse agonist. All
psychostimulants were stopped 14 days prior to the start of the study. The study started with
three weeks of flexible dosing based on the investigators discretion. Potential dosing amounts
included 10mg/20mg/or 40mg a day of Pitolisant or 100mg/200mg/ or 400mg a day of
Modafinil. This was followed by five weeks of stable dosing. ESS was used to score EDS at
baseline and at completion of the trial. In the intention-to-treat analysis, all three treatment
groups saw a decrease in ESS scores. Patients given the placebo saw the smallest improvement
in their ESS scores, with reductions of -3.4. While those in the modafinil and pitolisant treatment
groups saw greater improvements with reductions of –6.9 and -5.8 respectively (Table 4).
Pitolisant was determined to be superior compared to placebo and noninferior compared
to modafinil (Table 5). The non-inferiotirty of pitolisant versus modafinil was tested based on a
non-inferiority margin of 2 ESS points. This value was half the difference between modafinil and
placebo in previous trials (Mean change of 4.02, 95% CI 0.14-7.09).
Table 4: ESS scores throughout the trial
Baseline
Placebo Group
18.9 (2.5)
(n=30)
Pitolisant Group 17.8 (2.5)
(n=31)
Modafinil Group 18.5 (2.7)
(n=33)

Final
15.6 (4.3)

Change over Trial
-3.4 (4.2)

12.0 (6.2)

-5.8 (6.2)

11.6 (6.0)

-6.9 (6.2)
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Table 5: Treatment Effect (mean difference [95% CI]; p-value)
Pitolisant vs placebo
Pitolisant vs Modafinil
-3.0 (-5.6 to -0.4)
0.12 (-2.5 to 2.7)
p= 0.024
p=0.250
Nine severe adverse events occurred during the treatment period; 6 of these was regarded as
treatment related. One with pitolisant (abdominal discomfort) and five with modafinil
(abdominal pain, abnormal behavior, amphetamine-like withdrawal symptoms,
lymphoadenopathy, and inner ear disorder).
Lastly, the study done by Herring et al.17 was a RCT, double-blind, six sequence crossover study consisting of 125 patients with obstructive sleep apnea and refractory EDS. The study
was conducted at 26 sites across the United States. Participants were randomized into one of six
treatment sequences. All sequences included three periods of 2 week treatments of MK-0249 (an
H3 inverse agonist), Modafinil, and a placebo daily for 2 weeks. Periods 1 and 2 were followed
by a single-blind wash out period in which participants received a placebo daily for 1 week
before starting the next period in their respected sequence
Various doses of MK-0249 were used in the trial. Dosing options of MK-0249 included
3mg, 5mg, 8mg, 10mg and 12mg. An unblinded statistician determined the appropriate dose for
each participant. A total of 125 patients were randomized and 103 completed the study.
At the end of each treatment period, reevaluation of each participants EDS was assessed via the
ESS scale. All participants who had at least one end-point in at least one treatment period were
included in the full analysis set.
Unlike the previously discussed studies, in this study ESS was considered a secondary
end-point. A conditional approach was prespecified prior to the start of the study. Due to the
conditional nature of this approach, failure of the primary hypothesis also lead to the failure of
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the secondary hypotheses. Therefore, only descriptive results with a 95% CI for the treatment
difference were provided and no p-values were given.
Efficacy was seen most with the top two doses of MK-0249 (10mg + 12mg). These
dosages were combined into a single group for the analysis. All three groups displayed a
decrease in average ESS scores. MK-0249 saw the largest improvement with a decrease of 3.99,
while placebo and modafinil groups saw a smaller improvement with changes of -2.21 and -2.96,
respectively (Table 6). When compared to placebo, MK-0149 (10mg + 12mg) saw an
improvement of -1.78 in average ESS scores. This was a much larger improvement than the, 0.74 ESS difference, seen between modafinil and placebo (Table 7).
Change from baseline over 2 weeks
Placebo Group -2.21 (±0.76)
(n=116)
MK-0249
-3.99 (±1.01)
(10mg + 12 mg)
(n=74)
Modafinil
-2.96 (±0.79)
Group
(n=106)

MK 10+ 12 vs placebo Modafinil vs placebo
-1.78 (-2.78 to -0.78)
-0.74 (-1.60 to 0.11)
Table 7: Treatment Efficacy: ESS differences from placebo
in least squares mean (95% CI) change from baseline at
week 2

Table 6: Least squares mean (95% CI) ESS change
from baseline at week 2

Reasons for discontinuation in the 22 patients were AEs (N=12), withdrawal by patient (N=9)
and protocol violation (N=1). Patient compliance was evaluated by capsule counts at each visit.
Discussion:
The Herring et al.17 study was one of the first studies to be done assessing similar
therapeutic effects on OSA patients. Treatment with the H3 inverse agonist, MK-0249, showed
qualitative improvement in ESS scores when compared to baseline scores. However, while these
results are meaningful and should not be negated, they are not statistically significant. It is
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evident that more studies need to be done in order to appropriately assess the benefits of H3
inverse agonists in the OSA population.
The unique cross sequential design in the Lin J-S et al.15 study allowed the direct
comparison of the placebo and treatment effects on the same subject. One limitation of this study
design is the potential “carry over” effects between treatments. In the Lin J-S et al. study,
patients were asked to discontinue all stimulant medications, and receive one week of placebo
followed by one week of tiprolisant. It is possible that patients felt more tired than expected
while withdrawing from their stimulant medication. In addition, subject may have also perceived
a greater treatment effect from tiprolisant after a not receiving a stimulant for an entire week
prior. The study done by Herring et al.17 allowed a one week washout period between
interventions in order to try to eliminate this “carry over” effect.
The Dauvillers et al.16 and Herring et al.17 studies reported adverse events that resulted in
participation discontinuation. Throughout this review, there was only one serious adverse event
related to treatment with an H3 inverse agonist. The patient complained of abdominal pain and
was in the Dauvillers et al.16 study. The most common side effect noted in all three studies was
headache and anxiety. The Herring et al. study also had reports of insomnia with treatments
involving higher doses of the H3 inverse agonist. Further studies should be investigated to
determine the continuation of these effects with continued treatment.
It is important to remember that while both narcolepsy and OSA present with clinical
symptoms of EDS, the etiology of sleepiness is not the same in each condition. While narcolepsy
occurs due to a deficiency in a neuropeptide in the brain, OSA occurs as a result of a physical
obstruction of the airway. OSA patients have the physiological ability to regulate sleep-wake
cycles, while narcoleptic patients do not. The efficacy of H3 inverse agonists may be different

Peters | H3 Receptor Inverse Agonist & EDS | 11
between narcolepsy and OSA simply due to the nature of the conditions. Histamine may play a
more primary role in helping to better regulate the dysfunctional sleep-wake cycle in narcolepsy.
In contrast, the effects of additional histamine and arousal in OSA patients may just
symptomatically treat residual EDS.
Conclusion:
Life with excessive daytime sleepiness (EDS) can be debilitating, expensive, and
dangerous. All three studies discussed in this review, show promising results to suggest that
histamine H3 inverse agonists are effective in treating patients with sleep disorders. The two
studies involving narcoleptic participants provided the most promising evidence. Similar
findings in ESS score reduction were also seen in a new study recently published in early 2017
investigating the effects of pitolisant in reducing daily cataplexy attacks in narcoleptic patients.18
More studies should be done to prove the significance of H3 inverse agonist use in OSA patients.
Currently, there is a study finalizing the results of the use of an H3 inverse agonist in 202 OSA
patients; results are expected to be published in the near future.19 Additional future studies
should be done to investigate the long-term effects and/or tolerability to use of this new drug
class. As more is learned about the histaminergic system and the effects of histamine on arousal,
it is hopeful that more treatment options will become available for all patients suffering from
EDS.
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